The clinical trial will assess the safety of miroliverELAP for the treatment of acute liver failure, severe acute alcohol-associated hepatitis, or acute on chronic liver failure. miroliverELAP is an external liver assist combination product consisting of a single-use MIRO-001 bioengineered liver graft and an extracorporeal blood circuit. miroliverELAP Is intended to support the native (failed) liver for up to 48-hours of continuous treatment to allow time for liver recovery or to identify a transplantable liver.
This is a phase 1, open, single arm safety study of miroliverELAP for the treatment of acute liver failure (ALF), severe acute alcohol-associated hepatitis, or acute on chronic liver failure . Subjects who present with ALF, severe acute alcohol-associated hepatitis, or acute on chronic liver failure may be eligible for the study. Subjects will be treated with miroliverELAP continuously for 48 hours. The study will assess the safety of the miroliverELAP used to support liver function in an individual experiencing ALF, severe acute alcohol-associated hepatitis, or acute on chronic liver failure. Safety profile will be characterized by survival over the duration of therapy, tracking miroliverELAP-related adverse events, the proportion of subjects surviving 21-day post treatment initiation, and the difference in the values of specific biomarkers pre-treatment and at the time of treatment discontinuation; such as: albumin, ammonia, creatinine, INR, and lactate blood concentration. A minimum of 5 subjects will be treated for 48 hours and followed for 32 days. Up to 15 subjects may be enrolled in up to 8 study sites.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
Subject's blood will be perfused through a bioengineered liver graft via an extracorporeal blood circuit.
Northwestern Memorial Hospital
Chicago, Illinois, United States
RECRUITINGUniversity of Michigan Medical School
Ann Arbor, Michigan, United States
RECRUITINGUniversity of Minnesota Medical School
Minneapolis, Minnesota, United States
RECRUITINGMayo Clinic
Rochester, Minnesota, United States
RECRUITINGMount Sinai Recanati/Miller Transplantation Institute
New York, New York, United States
RECRUITINGCleveland Clinic Foundation
Cleveland, Ohio, United States
RECRUITINGIntermountain Healthcare
Salt Lake City, Utah, United States
RECRUITINGVirginia Commonwealth University Medical Center
Richmond, Virginia, United States
RECRUITINGSurvival
Survival over the duration of miroliverELAP treatment
Time frame: 48 hours
Adverse Events
Serious adverse events attributable to miroliverELAP
Time frame: 32 days
21-day survival
Survival for 21-days post initiation of miroliverELAP therapy
Time frame: 21 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.